Last reviewed · How we verify
NCT07114653
The Role of POLE Mutation in High Risk Endometrial Cancer.
trial in Endometrial Neoplasms in 150 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Far Eastern Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 September 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Taiwan |
Conditions studied
- Endometrial Neoplasms — all drugs for Endometrial Neoplasms →
Sponsor
Far Eastern Memorial Hospital
Who can join
Eligibility, female only, with Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is: What is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07114653
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Neoplasms
Currently open trials in the same condition.
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06023862 — A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurr · Phase 2 · recruiting
- NCT06003231 — A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 · Phase 2 · active not recruiting
Other Far Eastern Memorial Hospital trials
Trials by the same sponsor.
- NCT07385976 — The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients · not yet recruiting
- NCT07107542 — Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities · not yet recruiting
- NCT07105345 — Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD · NA · recruiting
- NCT07110350 — Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma · not yet recruiting
- NCT07114640 — The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Func · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07114653 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Far Eastern Memorial Hospital
- Last refreshed: 11 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07114653.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing